EXHIBIT 10.1 ------------ PATENT LICENSE AGREEMENT THIS AGREEMENT made and entered into and effective as of August 13, 2008, is by and between Network-1 Security Solutions, Inc., a Delaware corporation (the "Licensor") and Microsemi Corporation, a...Patent License Agreement • August 15th, 2008 • Network 1 Security Solutions Inc • Services-prepackaged software • New York
PATENT LICENSE AGREEMENT – EXCLUSIVEPatent License Agreement • October 15th, 2021
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
PATENT LICENCE AGREEMENT 4Patent License Agreement • December 29th, 2020
PATENT LICENSE AGREEMENT n° C-00061906Patent License Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
IP is owner of patents and patent applications relating to a method of homologous recombination. IP has already granted exploitation rights for these patents and patent application to third parties for specific applications and now wishes to share this technology with a new industrial partner.
EX-10.13 5 dex1013.htm LICENSE AGREEMENT WITH UNIVERSITY OF PENNSYLVANIA EXECUTION VERSION [CONFIDENTIAL TREATMENT REQUESTED] /*/ INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED...Patent License Agreement • May 5th, 2020 • Pennsylvania
This Patent License Agreement (this “Agreement”) is between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Aegerion Pharmaceuticals, Inc, a Delaware corporation (“Company”). This Agreement is effective on May 19, 2006 (the “Effective Date”).
EX-10.16 41 d358280dex1016.htm PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the...Patent License Agreement • May 5th, 2020 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
Patent License Agreement for Startups Agreement No.Patent License Agreement • July 20th, 2017 • Texas
This Patent and Technology License Agreement (“Agreement”) is between the Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas at El Paso (“UTEP”), a component institution of System (Board and UTEP together “Licensor”) and [Company Name] a [State] corporation with its principal place of business at [Company Address] (“Licensee”) (collectively, “Parties”, or singly, “Party”).
ContractPatent License Agreement • May 21st, 2014 • Globeimmune Inc • Pharmaceutical preparations • District of Columbia
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Certain identified information has been omitted from this exhibit because it is both (i) not material and brackets (“[…***…]”) in this exhibit.*** PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent...Patent License Agreement • January 16th, 2024 • Kyverna Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Shipping Information), Appendix G (Example Royalty Report), and Appendix H (Royalty Payment Options).
ContractPatent License Agreement • May 5th, 2020 • New York
EX-10.6 13 exhibit106s-1.htm EXHIBIT 10.6 Exhibit 10.6 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. PATENT LICENSE AGREEMENT THIS PATENT LICENSE AGREEMENT (the “Agreement”) is made effective as of January 1, 2017 (the “Effective Date”), by and between Keygene N.V. (“KeyGene”), a company organized and existing under the laws of The Netherlands and having its registered offices at Agro Business Park 90, 6708 PW Wageningen, The Netherlands, and Guardant Health, Inc., a company incorporated under the laws of the State of Delaware, and having an address at 505 Penobscot Drive, Redwood City, CA 94063 (“Licensee”) and relates to KeyGene Technology as defined hereinafter. KeyGene and Licensee may be referred to herein individually as a “Party” or collectively as the “Parties.” BACKGROUND WHEREAS, KeyGene is a biotechnology company acti
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT-NONEXCLUSIVE COVER PAGEPatent License Agreement • December 28th, 2011 • Mri Interventions, Inc. • Surgical & medical instruments & apparatus • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
Page 73 TITLE 35—PATENTS § 207Patent License Agreement • November 6th, 2019
agreement the invention was made upon a show- ing by the small business firm, nonprofit organi- zation, or assignee that reasonable but unsuc- cessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the cir- cumstances domestic manufacture is not com- mercially feasible.
PATENT LICENSE AGREEMENT by and between TECHNIPFMC PLC AND TECHNIP ENERGIES N.V. Dated as of February 15, 2021Patent License Agreement • March 25th, 2022 • Technip Energies N.V. • Services-engineering services • New York
SISVEL WIRELESS LICENSE AGREEMENTPatent License Agreement • January 18th, 2018
This Patent License Agreement (“Agreement”) is entered into by and between SISVEL INTERNATIONAL S.A., a company duly incorporated under the laws of Luxembourg with an office at 6, Avenue Marie Thérèse, L‐2132 Luxembourg, (“Sisvel”), and XYZ , a company duly incorporated under the laws of , with its principal office at , (“Licensee”).
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVEPatent License Agreement • March 22nd, 2024
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks), Appendix E (Commercialization Plan). Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
PATENT LICENSE AGREEMENTPatent License Agreement • May 23rd, 2005 • SmartMetric, Inc. • Miscellaneous manufacturing industries
AGREEMENT made and entered into as of the 1st day of August 2004, with revisions dated December 33, 2004 by and between Applied Cryptology, Inc., a Nevada corporation having its principal offices at [address] (the “Licensor”), and SmartMetric, Inc., a Nevada corporation having its principal offices at 67 Wall Street, Level 22, New York, New York 10005 (the “Company”).
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT —EXCLUSIVE COVER PAGEPatent License Agreement • May 21st, 2014 • Globeimmune Inc • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
Portions of this exhibit were omitted and filed separately with the Secretary of the Securities and Exchange Commission pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2...Patent License Agreement • July 7th, 2010 • Vishay Precision Group, Inc. • Electronic components & accessories • New York
This non-exclusive Patent License Agreement (“Agreement”) is entered into as of July 6, 2010 (the “Effective Date”), by and between Vishay Dale Electronics, Inc., a Delaware corporation (“Licensor”), and Vishay Precision Group, Inc. a Delaware corporation ("Licensee").
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT — EXCLUSIVE COVER PAGEPatent License Agreement • May 21st, 2014 • Globeimmune Inc • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
BACKGROUNDPatent License Agreement • July 2nd, 2003 • Interdigital Communications Corp • Patent owners & lessors • Delaware
Exhibit 10.10 PATENT LICENSE AGREEMENTPatent License Agreement • January 31st, 2001 • Wavesplitter Technologies Inc • Semiconductors & related devices • California
EX-10.2 3 d150860dex102.htm EX-10.2 CONFIDENTIAL PORTIONS OMITTED AGREEMENTPatent License Agreement • May 5th, 2020 • Washington
This Agreement (“Agreement”) is entered into as of October 5, 2010 (the “Effective Date”) by and among Digimarc Corporation, an Oregon corporation, with an address at 9405 SW Gemini Drive, Beaverton, OR 97008 (“Digimarc”), Invention Law Group, P.C. (“ILG”) and IV Digital Multimedia Inventions, LLC (“DMI” and together with ILG, the “IV Entities”).
PATENT LICENSE AGREEMENT AGT. NO.Patent License Agreement • April 10th, 2024 • Texas
Licensor owns rights to the Licensed Patents. Licensee desires to secure the right and license to use, develop, manufacture, market, and commercialize the Licensed Patents. Licensor has determined that such use, development, and commercialization of the Licensed Patents is in the public’s best interest and is consistent with Licensor’s educational and research missions and goals. Licensor desires to have the Licensed Patents developed and used for the benefit of Licensee, the inventors, Licensor, and the public.
PATENT LICENSE AGREEMENTPatent License Agreement • July 6th, 2020 • District of Columbia
This Agreement is entered into between the U.S. Government, as represented by the U.S. Department of Agriculture, Agricultural Research Service (hereinafter referred to as “USDA”) and (company name), a (state) corporation having offices at (street address, city, and state) (hereinafter referred to as “COMPANY”).
Exhibit 10.15 ------------- Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [*]. A complete version of this...Patent License Agreement • December 4th, 2001 • Rambus Inc • Semiconductors & related devices • Delaware
PATENT LICENSE AGREEMENT For NanoPulse TechnologyPatent License Agreement • May 3rd, 2016 • Pulse Biosciences, Inc. • Surgical & medical instruments & apparatus • California
EX-10 2 ex10-20.htm PATENT LICENSE AGREEMENT Execution Copy PATENT LICENSE AGREEMENT BETWEEN POLYMEDIX, INC. AND THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA PATENT LICENSE AGREEMENTPatent License Agreement • May 5th, 2020 • Pennsylvania
This Patent License Agreement (this “Agreement”) is made on January 3, 2003 (the “Effective Date”), by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at 3160 Chestnut Street, Suite 200, Philadelphia, Pennsylvania 19104-3147 (“Penn”), and Polymedix, Inc., a Delaware corporation (“Licensee”), with its principal offices at 5 Radnor Corporate Center, 100 Matsonford Road, Suite 520, Radnor, PA 19087.
Exhibit 10.1(l) PATENT LICENSE AGREEMENT This Patent License Agreement, effective the date last signed by the parties (April 17, 1996) hereinafter referred to as the "Agreement," is by and between: Washington University, located at One Brookings...Patent License Agreement • March 4th, 2002 • Athena Diagnostics Inc • Services-medical laboratories • Missouri
EX-10.10 12 d373760dex1010.htm EX-10.10 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT — EXCLUSIVE COVER PAGE For PHS internal use only:...Patent License Agreement • May 5th, 2020 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
PATENT LICENSE AGREEMENTPatent License Agreement • May 12th, 2021
[insert name], a company established and existing under the laws of [insert country], commercial registry code [insert code], located at [insert address] (Licensor), represented by [insert position and name], and
PATENT LICENSE AGREEMENTPatent License Agreement • July 6th, 2020 • District of Columbia
This Agreement is entered into between the U.S. Government, as represented by the U.S. Department of Agriculture, Agricultural Research Service (hereinafter referred to as “USDA”) and (company name), a (state) corporation having offices at (street address, city, and state) (hereinafter referred to as “COMPANY”).
Confidential Treatment Requested by Celera Corporation* HIGHLY CONFIDENTIAL EXECUTION VERSION REAL-TIME INSTRUMENT PATENT LICENSE AGREEMENTPatent License Agreement • May 5th, 2020 • California
This REAL-TIME INSTRUMENT PATENT LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of the 25th of April, 2006 (the “Effective Date”) by and among BECKMAN COULTER, INC., a Delaware corporation with its principal offices located at 4300 North Harbor Boulevard, Fullerton, California 92835 (the “Licensee”), and APPLERA CORPORATION, a Delaware Corporation, through its APPLIED BIOSYSTEMS group located at 850 Lincoln Centre Drive, Foster City, California 94404, and its CELERA GENOMICS group, located at 45 West Gude Drive, Rockville, Maryland 20850 (“Licensor”). Each of the parties to this Agreement shall be referred to individually as a “Party” and collectively as the “Parties”.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS THROUGHOUT THIS EXHIBIT....Patent License Agreement • June 29th, 2020 • ScoutCam Inc. • Optical instruments & lenses
This PATENT LICENSE AGREEMENT (“Agreement”), is dated as of December 1, 2019, made effective as of December 1, 2019 (“Effective Date”), by and between Medigus Ltd., a company organized under the laws of the State of Israel (“Licensor”) and ScoutCam Ltd., a company organized under the laws of the State of Israel (“Licensee”). Licensor and Licensee are each referred to herein separately as “Party” and are referred to herein collectively as the “Parties.”
EX-10 6 filename6.htm Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. CONFIDENTIAL UNIVERSITY of PENNSYLVANIA Patent License AgreementPatent License Agreement • May 5th, 2020 • Pennsylvania
This Patent License Agreement (this “Agreement”) is between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Apellis AG, a company organized and existing under the laws of Switzerland (“Company”). This Agreement is being entered into by and between Penn and Company on March 28, 2008 (the “Effective Date”).
THIS PATENT LICENSE AGREEMENT (the "Agreement") MADE BETWEEN:Patent License Agreement • May 1st, 2023 • New York
EVRYTHNG LIMITED, a corporation organized under the laws of the United Kingdom (hereinafter "EVRYTHNG") whose address is: Unit 4, 122 East Road, London N1 6FB, United Kingdom,
